Functional glucokinase regulator gene variants have inverse effects on triglyceride and glucose levels, and decrease the risk of obesity in children

Diabetes and Metabolism

Volumn 37, Issue 5, 2011, Pages 432-439

  Horvatovich, K ^a   Bokor, S ^b   Polgar, N ^a   Kisfali, P ^a   Hadarits, F ^c   Jaromi, L ^a   Csongei, V ^a   Repasy, J ^b   Molnar, D ^b   Melegh, B ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

^c Markusovszky Teaching Hospital   (Hungary)

Author keywords

Children; Fasting plasma glucose; GCKR; Glucokinase Regulatory Protein; Obesity; Serum triglyceride

Indexed keywords

GLUCOKINASE;

ADOLESCENT; ALLELE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HETEROZYGOTE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POLYMERASE CHAIN REACTION; REGULATOR GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADOLESCENT; BLOOD GLUCOSE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; INCIDENCE; LINKAGE DISEQUILIBRIUM; MALE; OBESITY; RISK FACTORS; TRIGLYCERIDES;

EID: 81055138738     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2011.02.003     Document Type: Article

References (43)

1. Csabi G., Torok K., Jeges S., Molnar D. Presence of metabolic cardiovascular syndrome in obese children. Eur J Pediatr 2000, 159:91-94.
2. Mansoub S., Chan M.K., Adeli K. Gap analysis of pediatric reference intervals for risk biomarkers of cardiovascular disease and the metabolic syndrome. Clin Biochem 2006, 39:569-587.
3. Must A., Spadano J., Coakley E.H., Field A.E., Colditz G., Dietz W.H. The disease burden associated with overweight and obesity. JAMA 1999, 282:1523-1539.
4. Elston R.C., Namboodiri K.K., Nino H.V., Pollitzer W.S. Studies on blood and urine glucose in Seminole Indians: indications for segregation of a major gene. Am J Hum Genet 1974, 26:13-34.
5. Rich S.S. Mapping genes in diabetes. Genetic epidemiological perspective. Diabetes 1990, 39:1315-1319.
6. Hanson R.L., Elston R.C., Pettitt D.J., Bennett P.H., Knowler W.C. Segregation analysis of non-insulin-dependent diabetes mellitus in Pima Indians: evidence for a major-gene effect. Am J Hum Genet 1995, 57:160-170.
7. Stern M.P., Mitchell B.D., Blangero J., Reinhart L., Krammerer C.M., Harrison C.R., et al. Evidence for a major gene for type II diabetes and linkage analyses with selected candidate genes in Mexican-Americans. Diabetes 1996, 45:563-568.
8. Matschinsky F.M., Glucokinase glucose homeostasis, and diabetes mellitus. Curr Diab Rep 2005, 5:171-176.
9. Van Schaftingen E., Vandercammen A., Detheux M., Davies D.R. The regulatory protein of liver glucokinase. Adv Enzyme Regul 1992, 32:133-148.
10. Hayward B.E., Dunlop N., Intody S., Leek J.P., Markham A.F., Warner J.P., et al. Organization of the human glucokinase regulator gene GCKR. Genomics 1998, 49:137-142.
11. Warner J.P., Leek J.P., Intody S., Markham A.F., Bonthron D.T. Human glucokinase regulatory protein (GCKR): cDNA and genomic cloning, complete primary structure, and chromosomal localization. Mamm Genome 1995, 6:532-536.
12. Brocklehurst K.J., Davies R.A., Agius L. Differences in regulatory properties between human and rat glucokinase regulatory protein. Biochem J 2004, 378:693-697.
13. Garcia-Herrero C.M., Galan M., Vincent O., Flández B., Gargallo M., Delgado-Alvarez E., et al. Functional analysis of human glucokinase gene mutations causing MODY2: exploring the regulatory mechanisms of glucokinase activity. Diabetologia 2007, 50:325-333.
14. Agius L. Glucokinase and molecular aspects of liver glycogen metabolism. Biochem J 2008, 414:1-18.
15. Hayward B.E., Fantes J.A., Warner J.P., Intody S., Leek J.P., Markham A.F., et al. Co-localization of the ketohexokinase and glucokinase regulator genes to a 500-kb region of chromosome 2p23. Mamm Genome 1996, 7:454-458.
16. Grimsby J., Coffey J.W., Dvorozniak M.T., Magram J., Li G., Matschinsky F.M., et al. Characterization of glucokinase regulatory protein-deficient mice. J Biol Chem 2000, 275:7826-7831.
17. Van Schaftingen E., Detheux M., Veiga da C.M. Short-term control of glucokinase activity: role of a regulatory protein. FASEB J 1994, 8:414-419.
18. Veiga-da-Cunha M., Delplanque J., Gillain A., Bonthron D.T., Boutin P., Van Schaftingen E., et al. Mutations in the glucokinase regulatory protein gene in 2p23 in obese French caucasians. Diabetologia 2003, 46:704-711.
19. Saxena R., Voight B.F., Lyssenko V., Burtt N.P., de Bakker P.I., Chen H., Roix J.J., et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007, 316:1331-1336.
20. Sparso T., Andersen G., Nielsen T., Burgdorf K.S., Gjesing A.P., Nielsen A.L., et al. The GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced risk of type 2 diabetes. Diabetologia 2008, 51:70-75.
21. Qi Q., Wu Y., Li H., Loos R.J., Hu F.B., Sun L., et al. Association of GCKR rs780094, alone or in combination with GCK rs1799884, with type 2 diabetes and related traits in a Han Chinese population. Diabetologia 2009, 52:834-843.
22. Vaxillaire M., Cavalcanti-Proenca C., Dechaume A., Tichet J., Marre M., Balkau B., et al. The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population. Diabetes 2008, 57:2253-2257.
23. Johansen C.T., Wang J., Lanktree M.B., Cao H., McIntyre A.D., Ban M.R., et al. Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet 2010, 42:684-687.
24. Tam C.H., Ma R.C., So W.Y., Wang Y., Lam V.K., Germer S., et al. Interaction effect of genetic polymorphisms in glucokinase (GCK) and glucokinase regulatory protein (GCKR) on metabolic traits in healthy Chinese adults and adolescents. Diabetes 2009, 58:765-769.
25. Cole T.J., Bellizzi M.C., Flegal K.M., Dietz W.H. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000, 320:1240-1243.
26. de Ferranti S.D., Gauvreau K., Ludwig D.S., Neufeld E.J., Newburger J.W., Rifai N. Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey. Circulation 2004, 110:2494-2497.
27. Neel J.V. Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress" ?. Am J Hum Genet 1962, 14:353-362.
28. Tuomilehto J., Wolf E. Primary prevention of diabetes mellitus. Diabetes Care 1987, 10:238-248.
29. Hamman R.F. Genetic and environmental determinants of non-insulin-dependent diabetes mellitus (NIDDM). Diabetes Metab Rev 1992, 8:287-288.
30. Ohlson L.O., Larsson B., Bjorntorp P., Eriksson H., Svärdsudd K., Welin L., et al. Risk factors for type 2 (non-insulin-dependent) diabetes mellitus. Thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913. Diabetologia 1988, 31:798-805.
31. Manson J.E., Rimm E.B., Stampfer M.J., Colditz G.A., Willett W.C., Krolewski A.S., et al. Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. Lancet 1991, 338:774-778.
32. Harris M.I. Impaired glucose tolerance in the U.S. population. Diabetes Care 1989, 12:464-474.
33. The DECODE study group, European Diabetes Epidemiology Group Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999, 354:617-621.
34. Hattersley A.T., Turner R.C., Permutt M.A., Patel P., Tanizawa Y., Chiu K.C., et al. Linkage of type 2 diabetes to the glucokinase gene. Lancet 1992, 339:1307-1310.
35. Njolstad P.R., Sovik O., Cuesta-Munoz A., Bjørkhaug L., Massa O., Barbetti F., et al. Neonatal diabetes mellitus due to complete glucokinase deficiency. N Engl J Med 2001, 344:1588-1592.
36. Slosberg E.D., Desai U.J., Fanelli B., St Denny I., Connelly S., Kaleko M., et al. Treatment of type 2 diabetes by adenoviral-mediated overexpression of the glucokinase regulatory protein. Diabetes 2001, 50:1813-1820.
37. O'Doherty R.M., Lehman D.L., Telemaque-Potts S., Newgard C.B. Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia. Diabetes 1999, 48:2022-2027.
38. Ferre T., Riu E., Bosch F., Valera A. Evidence from transgenic mice that glucokinase is rate limiting for glucose utilization in the liver. FASEB J 1996, 10:1213-1218.
39. Willer C.J., Sanna S., Jackson A.U., Scuteri A., Bonnycastle L.L., Clarke R., et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 2008, 40:161-169.
40. Teslovich T.M., Musunuru K., Smith A.V., Edmondson A.C., Stylianou I.M., Koseki M., et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010, 466:707-713.
41. Orho-Melander M., Melander O., Guiducci C., Perez-Martinez P., Corella D., Roos C., et al. Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes 2008, 57:3112-3121.
42. Beer N.L., Tribble N.D., McCulloch L.J., Roos C., Johnson P.R., Orho-Melander M., et al. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 2009, 18:4081-4088.
43. Illig T., Gieger C., Zhai G., Römisch-Margl W., Wang-Sattler R., Prehn C., et al. A genome-wide perspective of genetic variation in human metabolism. Nat Genet 2010, 42:137-141.